Synergism of desbutyl-benflumetol and retinol against Plasmodium falciparum in vitro
- PMID: 16416384
- DOI: 10.1007/s00508-005-0446-4
Synergism of desbutyl-benflumetol and retinol against Plasmodium falciparum in vitro
Abstract
This in vitro study was conducted to assess the blood schizontocidal activity of desbutyl-benflumetol (DBB), a new benzindene derivative, retinol and a combination of both compounds. The tests were carried out according to the methodology of the WHO standard test Mark II, measuring the drug-dependent inhibition of schizont maturation, and using 43 fresh isolates of Plasmodium falciparum from northwestern Thailand, an area with established multidrug-resistance. DBB and retinol showed a mean 50% effective concentration (EC-50) of 3.73 nM and 466.86 nM and 90% effective concentration (EC-90) of 19.83 nM and 5531.69 nM respectively. The combination of DBB and 3.50 muM retinol showed strong inhibition of schizont maturation, with an EC-90 for DBB of 0.67 nM. At the therapeutically relevant EC-99, the combination was about 10 times more effective than expected, suggesting that retinol potentiated the effect of DBB. A concentration of 3.50 muM retinol corresponds to the 95th percentile of the physiological serum levels. It is well known that retinol levels are significantly decreased in acute falciparum malaria. Supplementation with retinol during malaria treatment may improve the therapeutic results of blood schizontocides of the fluorene class.
Similar articles
-
Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.Wien Klin Wochenschr. 2007;119(19-20 Suppl 3):53-9. doi: 10.1007/s00508-007-0870-8. Wien Klin Wochenschr. 2007. PMID: 17987359
-
Specific pharmacokinetic interaction between lumefantrine and monodesbutyl-benflumetol in Plasmodium falciparum.Wien Klin Wochenschr. 2007;119(19-20 Suppl 3):60-6. doi: 10.1007/s00508-007-0861-9. Wien Klin Wochenschr. 2007. PMID: 17987360
-
In vitro activity of artemisinin alone and in combination with retinol against Plasmodium falciparum.Wien Klin Wochenschr. 2005;117 Suppl 4:45-8. doi: 10.1007/s00508-005-0447-3. Wien Klin Wochenschr. 2005. PMID: 16416385 Clinical Trial.
-
pfmdr1 (Plasmodium falciparum multidrug drug resistance gene 1): a pivotal factor in malaria resistance to artemisinin combination therapies.Expert Rev Anti Infect Ther. 2017 Jun;15(6):527-543. doi: 10.1080/14787210.2017.1313703. Epub 2017 Apr 10. Expert Rev Anti Infect Ther. 2017. PMID: 28355493 Review.
-
Drug resistance in Plasmodium falciparum malaria.Infection. 1999;27 Suppl 2:S55-8. doi: 10.1007/BF02561674. Infection. 1999. PMID: 10885831 Review.
Cited by
-
Efficacy and safety of artesunate-amodiaquine and artemether-lumefantrine and prevalence of molecular markers associated with resistance, Guinea: an open-label two-arm randomised controlled trial.Malar J. 2020 Jun 24;19(1):223. doi: 10.1186/s12936-020-03290-w. Malar J. 2020. PMID: 32580771 Free PMC article. Clinical Trial.
-
Synergistic interaction between monodesbutyl-benflumetol and retinol in Plasmodium falciparum.Wien Klin Wochenschr. 2007;119(19-20 Suppl 3):53-9. doi: 10.1007/s00508-007-0870-8. Wien Klin Wochenschr. 2007. PMID: 17987359
-
Pharmacodynamic interaction between 4-aminoquinolines and retinol in Plasmodium falciparum in vitro.Wien Klin Wochenschr. 2008;120(19-20 Suppl 4):74-9. doi: 10.1007/s00508-008-1079-1. Wien Klin Wochenschr. 2008. PMID: 19066778
-
Synergism between quinine and retinol in fresh isolates of Plasmodium falciparum.Wien Klin Wochenschr. 2008;120(19-20 Suppl 4):69-73. doi: 10.1007/s00508-008-1078-2. Wien Klin Wochenschr. 2008. PMID: 19066777
-
Desbutyl-lumefantrine is a metabolite of lumefantrine with potent in vitro antimalarial activity that may influence artemether-lumefantrine treatment outcome.Antimicrob Agents Chemother. 2011 Mar;55(3):1194-8. doi: 10.1128/AAC.01312-10. Epub 2011 Jan 3. Antimicrob Agents Chemother. 2011. PMID: 21199927 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical